A US judge on Friday approved German chemical giant Bayer's $7.25 billion (€6.60 billion) settlement of lawsuits claiming its Roundup weedkiller causes cancer.
Judge Timothy Boyer in the US state of Missouri ruled that the agreement was "fair, reasonable, and adequate."
The decision could help Bayer end years of costly legal battles over Roundup, which the company acquired when it bought US weedkiller producer Monsanto in 2018.
"The court's final approval is a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup litigation," Bayer CEO Bill Anderson said.
The agreement covers tens of thousands of people who say they developed non-Hodgkin lymphoma, a type of blood cancer, after using Roundup.
It also covers people who may be diagnosed with the disease in the future after previous exposure to the weedkiller.
Bayer will pay up to $7.25 billion into a special fund over the next 21 years.
Individual payments are expected to average between $10,000 and $165,000. The amount will depend on factors including the patient's age, the severity of the illness and how long they were exposed to Roundup.
Some lawyers representing cancer patients have criticized the payments as too low.
But the judge rejected their objections, saying that further delays could leave seriously ill patients waiting years for compensation.